385 related articles for article (PubMed ID: 23893349)
1. Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease.
Virgone-Carlotta A; Uhlrich J; Akram MN; Ressnikoff D; Chrétien F; Domenget C; Gherardi R; Despars G; Jurdic P; Honnorat J; Nataf S; Touret M
Glia; 2013 Oct; 61(10):1645-58. PubMed ID: 23893349
[TBL] [Abstract][Full Text] [Related]
2. Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model.
Tentillier N; Etzerodt A; Olesen MN; Rizalar FS; Jacobsen J; Bender D; Moestrup SK; Romero-Ramos M
J Neurosci; 2016 Sep; 36(36):9375-90. PubMed ID: 27605613
[TBL] [Abstract][Full Text] [Related]
3. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
[TBL] [Abstract][Full Text] [Related]
4. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.
Walsh S; Gavin A; Wyatt S; O'Connor C; Keeshan K; Nolan YM; O'Keeffe GW; Sullivan AM
Int J Neurosci; 2015 Jan; 125(1):70-7. PubMed ID: 24628580
[TBL] [Abstract][Full Text] [Related]
7. Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
Jang H; Kim S; Lee JM; Oh YS; Park SM; Kim SR
Neuroreport; 2017 Mar; 28(5):242-249. PubMed ID: 28178069
[TBL] [Abstract][Full Text] [Related]
8. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Shan S; Hong-Min T; Yi F; Jun-Peng G; Yue F; Yan-Hong T; Yun-Ke Y; Wen-Wei L; Xiang-Yu W; Jun M; Guo-Hua W; Ya-Ling H; Hua-Wei L; Ding-Fang C
Neurobiol Aging; 2011 Mar; 32(3):443-58. PubMed ID: 19368990
[TBL] [Abstract][Full Text] [Related]
9. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
10. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Iancu R; Mohapel P; Brundin P; Paul G
Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
[TBL] [Abstract][Full Text] [Related]
11. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
12. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.
Zhang FL; He Y; Zheng Y; Zhang WJ; Wang Q; Jia YJ; Song HL; An HT; Zhang HB; Qian YJ; Tong YL; Dong L; Wang XM
CNS Neurosci Ther; 2014 Dec; 20(12):1036-44. PubMed ID: 25399812
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
15. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
[TBL] [Abstract][Full Text] [Related]
16. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Locke CJ; Fox SA; Caldwell GA; Caldwell KA
Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411
[TBL] [Abstract][Full Text] [Related]
17. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
18. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
19. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
20. Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease.
Depboylu C; Stricker S; Ghobril JP; Oertel WH; Priller J; Höglinger GU
Exp Neurol; 2012 Dec; 238(2):183-91. PubMed ID: 22964486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]